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eply
e thank Drs. Saravanan and Davidson for their insightful
omments regarding details of our omega-3 polyunsaturated fatty
cid (-3 PUFA) review and appreciate the opportunity to clarify
ssues that might have been prone to misinterpretation (1). We did
ot imply that the DART (Diet and Reinfarction) study (2),
ISSI Prevenzione (Gruppo Italiano per lo Studio della Soprav-
ivenza nell’ Infarto Miocardico–Prevenzione) study (3) and
ELIS study (Japan EPA Lipid Intervention Study) (4) were trials
ith a uniform population but in fact stated that they represent an
ggregate of evidence toward both secondary and primary preven-
ion. They correctly point out that the DART study (2) and the
ISSI-Prevenzione study (3) are secondary prevention studies
ith a significant -3 PUFA benefit in over 13,000 post-
yocardial infarction patients. However, even in secondary pre-
ention, not all studies have demonstrated benefit (1). The JELIS
rial (4), in contrast, tested the effects of eicosapentaenoic acid
EPA) in mostly a primary prevention cohort (n  14,981 with
ypercholesterolemia treated with statins). Here, the effect size was
ssentially identical (18% vs. 19%) to that seen in the secondary
revention group (n  3,664), but the 5-year event rate was nearly
-fold higher in the secondary prevention group (12% vs.  2%).
s Drs. Saravanan and Davidson correctly point out, in the entire
rimary prevention group, the benefits of EPA were not quite
tatistically significant (hazard ratio: 0.82; 95% confidence interval:
.63 to 1.06; p  0.13). In a subgroup of JELIS primary
revention patients (5), those with triglycerides 150 mg/dl and
igh-density lipoprotein cholesterol 40 mg/dl had event rates
hat were nearly 2-fold higher than those without this lipid
attern. In patients with this high-risk lipid combination, EPA
educed major cardiac event rates by 53% (p  0.043). Along with
he notable epidemiological data, we believe that the overall
vidence suggests benefits of -3 PUFA at least in high-risk risk
rimary prevention patients as well as in those needing secondary
revention of coronary heart disease.
We agree with Drs. Saravanan and Davidson that our single,
rief paragraph on the impact of -3 PUFA in atrial fibrillation
AF) was oversimplified (in an effort to make a lengthy review
ore concise). Although the observational study by Mozaffarian
t al. (6) suggested that high fish intake was associated with a 30%
eduction in AF over 12 years, the Rotterdam Study (7) found no
uch effect. Only 1 small randomized controlled study of 160
ost-bypass patients was performed to assess the benefits of -3UFA on the development of postoperative AF (8). The results of
his small study were remarkable in support of -3 PUFA,
ncluding 18.1% absolute risk reduction and 54.4% relative risk
eduction (or only 5.5 patients needed to be treated to prevent 1
pisode of AF). As this study points out and as we have discussed
lsewhere in more detail (9), these results compare favorably to the
esults of another large meta-analysis (58 studies including 8,565
articipants) (10), which examined the effects of amiodarone,
otalol, and beta blockers on post-bypass AF. In comparison, the
esults with -3 PUFA post-bypass seem to be similar or even
uperior to these other treatments to prevent AF. Clearly, larger
tudies are needed and some are underway (11) to assess the impact
f -3 PUFA in primary and secondary prevention of AF.
dditionally, higher doses of -3 PUFA (e.g., 2 to 5 g/day) need
o be studied in various cardiovascular diseases (CVD), including
F, and studies are needed to determine the relative benefits of
PA and docosahexaenoic acid (DHA) in CVD. It also is not
nown what impact DHA or EPA alone has in disease modifica-
ion, these areas being the subject of intense ongoing investigation.
Finally, we agree with Drs. Saravanan and Davidson that one
ould debate the details of the strengths and weaknesses of each
tudy. However, we believe the totality of the evidence suggests an
verall beneficial effect of -3 PUFA for CVD protection, a view
hat we are not alone in professing (12–14).
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o the Results of the
erman Pilot Phase of the
uroCMR Registry Indicate That
he Chasm Has Been Crossed?
eoffrey Moore (1) in his landmark book about the technology
doption lifecycle, “Crossing the Chasm,” divides the adopters into
phases—innovators, early adopters, the early majority, the late
ajority, and the laggards—with the curve forming a typical
istribution curve with the major hump comprising the early and
he late majority. Psychologically, others have classified these
roups as technology enthusiasts (innovators), visionaries (early
dopters), pragmatists (early majority), conservatives (late major-
ty), and skeptics (laggards). Moore proposed that, for various
easons, there exists a chasm between the early adopters and the
arly majority and the success of any technological innovation
epends on the capability of the technology to cross this chasm.
The results of the EuroCMR (European Cardiovascular Mag-
etic Resonance) Registry (2) seem to suggest that, at least in
ermany, cardiac magnetic resonance imaging (MRI) has been
ble to cross this chasm with its value being understood and
xploited for improving clinical care. Until now cardiac MRI has
emained a niche exam with numerous cardiac MRI units per-
orming studies for patients with congenital heart disease, cardiac
asses, pericardial disease, aortic pathology, and angiography. The
se of cardiac MRI in cardiomyopathies and ischemic heart disease
as clearly changed the status of this technique in our diagnostic
rmamentarium. Because ischemic heart disease comprises the
argest component of patients in contemporary clinical practice,
he use of cardiac MRI in this arena for ischemia and viability
ssessment would seem to suggest that cardiac MRI has “crossed
his chasm” and is now believed to be ready for primetime by
ardiologists who do not perform cardiac MRI (because they
ould comprise the early and the late majority in Moore’s
escription).
To be sure this has happened, which is welcome. Given the
otential of this technique, we wish to clarify the following points: p. Of the referrals made, how many were made by physicians who
actively perform cardiac MRI and by those who do not perform
cardiac MRI? This information would eliminate the potential
for a referral bias by those who perform this technique. In
23.1% of patients, cardiac MRI was the first technique or-
dered—who referred these patients? We consider any referral
from any member of any cardiac MRI group to be a potential
self-referral—this could simply mean that those who perform
the technique might be able to decide which patient might be
best suited for a cardiac MRI study.
. In the subgroup of those who underwent cardiac MRI as the
first study, all imaging needs were satisfied in 80.3%. Some
information in the remaining 20% who required further studies
would be helpful for understanding the limitations of cardiac
MRI.
. We are also interested to know the reasons why 11% of those
who underwent viability assessment by cardiac MRI still re-
quired a subsequent transthoracic echocardiography, because
cardiac MRI is now considered the practical gold standard for
viability assessment. We acknowledge that the reasons might be
other than viability assessment.
. A total of 5,025 patients in the centers in the registry
underwent cardiac MRI for suspected coronary artery disease/
ischemia assessment and determination of viability. It would be
very informative to know the number of single-photon emission
computed tomography and echocardiographic studies ordered
in these centers for the same reasons, because this would reflect
the positioning of the cardiac MRI study in the routine clinical
practice in the centers that participated in the registry.
The authors have made a laudable effort in extending the use of
very valuable technique. If the clarifications we request indicate
hat the chasm has not been crossed by cardiac MRI, we hypoth-
size that the presentation of prognostic data based on cardiac
RI studies might be the eventual trigger and the authors have
ccurately emphasized the need for extension of their work.
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eply
e deeply appreciate Drs. Thomas and Tavares’ interest in our paper
1) and welcome their important points for further clarification.
We easily admit that some of us are enthusiasts (innovators),
ome are even visionaries (early adopters), but the majority are very
ragmatic people who want cardiac magnetic resonance (CMR) to
